Mersana Therapeutics Inc. (NASDAQ:MRSN) changes shares on Tuesday trading session, with a change of -0.88% or -$0.19 shares. The trading starts at $22.00 and closed at $21.50 throughout the day. The trading session low price was $20.91 and day high was $24.04 on Tuesday, June 23. After the session, the Healthcare sector daily volume shifted to 1.69 million while its average volume is 2.21M. In other hand, the MRSN market cap reached to $1.50B. While, its current target price is $21.31 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -3.14% and up 115.25% for month. Its quarterly performance was 246.50% above, while its half year performance is up 355.34%. MRSN yearly performance stood at positive 427.48% and rise 271.90% for year-to-date. Current recommendation for Mersana Therapeutics Inc. is 1.30.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. MRSN EPS (TTM) for 12-month is -1.40. EPS for this year is 76.80%, while for the next year its value is -1.20. Its EPS Q/Q reached -150.70%.
Let’s take a look on the analyst recommendations on MRSN for the current month and previous month. For the current month, 5 of 6 analysts recommend stock as Buy while 0 as Sell, 1 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 7 analysts participate in stock recommendation. Out of 7, 1 rated it sell, 5 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $21.00-$27.00. Average target price for MRSN was reached at $24.80.
NEA Management Company, LLC, Sarissa Capital Management, LP and Blackrock Inc. are the top three holders in Mersana Therapeutics Inc. (MRSN) stock. On Mar 30, 2020, NEA Management Company, LLC has 11.96 million shares which valued 69.75 million. On Mar 30, 2020, Sarissa Capital Management, LP owned 3.75 million shares which valued at 21.86 million. On Mar 30, 2020, Blackrock Inc. has a total of 3.29 million shares which valued at 19.16 million. In the end, Blackrock Inc. have 5.58% shares outstanding of Mersana Therapeutics Inc. (MRSN) on Mar 30, 2020. The insider ownership moved to 0.80% and institutional holding shifted to 61.90%.
The company posted an EPS (TTM) of -1.40. According to the most recent quarter report on (Jun 2020), 7 analysts estimated an average EPS of -0.32, while -0.36 EPS posted a year ago period. Analyst Estimated EPS for MRSN published in the report was -0.37–0.28 during the same period. Comparing with last year, the average estimated EPS was -0.36 which is lower than -0.35 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for MRSN rise 209.17% for period of 200 days. SMA for 50 days was 56.90% which is showing green signal, while SMA-20 was 6.62%. The moving average value for Mersana Therapeutics Inc. (MRSN) is 9.11 and 15.62 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in MRSN stock. On Jun 01, Alleva Lawrence M, Director, bought 1,085 trading shares at the cost of $22.95, which valued at 24901.0. On Apr 14, SANDELL SCOTT D, 10% Owner, sold 548 shares at the cost of $9.22, with total shares of 0. On Apr 13, SANDELL SCOTT D, 10% Owner, sold 1,650 shares at the cost of 8.98. After this transaction, SANDELL SCOTT D total shares reached to 0 which valued at 14812.0.